reports
- GlobalData Healthcare Department
Lion Biotechnologies Inc (LBIO) - Financial Analysis Review
Lion Biotechnologies Inc (LBIO) - Financial Analysis Review Summary Lion Biotechnologies Inc (Lion Biotechnologies) develops and commercializes cancer immunotherapies based in tumor infiltrating lymphocytes (TILs). The company lead candidate TIL LN – 144, an autologous T-cell therapy, being developed for the treatment of metastatic melanoma and is in Phase 2 clinical trials. Lion Biotechnologies develops products using TIL technology for the treatment of solid tumors such as colorectal, ovar...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.